I.s.f. Societa Per Azioni

Neurotune Ag

Smithkline Beecham Corporation

Isf S.p.a.

Nikem Research S.r.l.

Other

Smithkline Beecham Farmaceutici S.p.a

Metys Pharmaceuticals Ag

Smithkline Beecham Farmaceutica S.p.a.

Smithkline Beecham Farmaceutici

Societe I.s.f. S.p.a.

Carlo Farina

Mario Pinza

Luca Francesco Raveglia

Mario Grugni

Stefania Gagliardi

Carla Ghelardini

Giuseppe Arnaldo Maria Giardina

Alberto Cerri

Giorgio Pifferi

Ugo C Pfeiffer

Silvano Banfi

Carlo Parini

Paola Petrillo

Maria T Riccaboni

Giuseppe Giardina

Guy Marguerite Marie Gerard Nadler

Marisa Martinelli

Guy Marguerite Nadler

Francesco Parravicini

Michael Scherz

Jacopo Roletto

Shahzad Sharooq Rahman

Stefano Gobbato

Michel Jean Martin

Pietro A Novella

Guy Marguerite Marie G&eacute;rard Nadler

Ruggero Fariello

Marcel Morvan

M Grugni

Giuseppe Arnaldo Giardina

Marcel Jean-Marie Morvan

Afro Gamba

Achille Umani-Ronchi

Gaetano Clavenna

Lorenzo Di Cesare Mannelli

Stefano Gobbatto

The present invention relates to a composition of enantiomers of 3,6,7,7a-tetrahydro-1H-pyrrolo[1,5-a]imidazole-2,5-dione and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment.

Synergistic compositions comprising (R)-dimiracetam (1) and (S)-dimiracetam (2) in a non-racemic ratio

The present invention provides a method of treatment, prevention and/or delay of progression of neuropathic pain by a specific dosing regime of acetam derivatives.

Acetam derivatives for pain relief

The invention relates to a method of manufacture of dimiracetam (2,5-dioxohexahydro-1 H-pyrrolo[1,2-a]imidazole), characterized in that a 4-oxo-butanoic acid ester is condensed with glycinamide in a one-pot reaction with a controlled pH. The reaction may be performed in aqueous solution or in an anhydrous lower alcohol solution.

Process for the preparation of dimiracetam

The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.

Use of dimiracetam in the treatment of chronic pain

The use of a compound of formula (I), is disclosed in treating and/or preventing 5 chemotherapy-induced peripheral neurotoxicity (CIPN). The invention includes pharmaceutical compositions wherein the compound of formula (I) is present in a mixture with anticancer agents. An improved anticancer treatment with reduced CIPN-related side effects is also provided. 

Pyrrolo[1,2-A]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents

Described herein are new bicyclic arylimidazolones having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and anti hyperalgesic action; also described is the process for their preparation and pharmaceutical compositions comprising them, useful for the treatment of cognitive deficits, and of various types of pain.

Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof

Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents

NKreceptor antagonists of formula (I): are useful in treating inter alia pulmonary disorders, CNS disorders and neurodegenerative disorders.

Quinoline derivatives

A compound of formula (I) or a salt thereof, or a solvate thereof, wherein: X represents oxygen, sulphur, or NR; Y and Z each independently represent nitrogen, CH, CRor CR; A represents an unsubstituted or substituted aryl group or an unsubstituted or substituted heterocyclyl group; Rrepresents &#x2014;C(O)NRR; Rand Reach independently represents hydrogen or specific substituents; and the use of such a compound in the treatment and/or prophylaxis of diseases associated with over activity of osteoclasts in mammals.

Azolylbenzamides and analogues and their use for treating osteoporosis

A compound of formula (I):or a salt thereof, or a solvate thereof, wherein Ra represents a group Rwhich is hydrogen, alkyl or optionally substituted aryl and Rb represents a moiety of formula (a):wherein X represents a hydroxy or an alkoxy group wherein the alkyl group may be substitued or unsubstituted or X represents a group NRRwherein Rand Reach independently represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, an optionally substituted heterocyclic group or an optionally substituted heterocyclylalkyl group, or Rand Rtogether with the nitrogen to which they are attached form a heterocyclic group; Rrepresents an alkyl or a substituted or unsubstituted aryl group; and R, Rand Reach independently represent hydrogen, alkyl, aryl or substituted aryl; Rand Reach independently represent hydrogen, hydroxy, amino, alkoxy, optionally substituted aryloxy, optionally substituted benzyloxy, alkylamino, dialkylamino, halo, trifluoromethyl, trifluoromethoxy, nitro, alkyl, carboxy, carbalkoxy, carbamoyl, alkylcarbamoyl, or Rand Rtogether represent methylenedioxy, carbonyldioxy or carbonyldiamino; and Rrepresents hydrogen, hydroxy, alkynoyl, alkyl, aminoalkyl, hydroxyalkyl, carboxyalky, carbalkoxyalkyl, carbamoyl or aminosulphonyl; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

Indole derivatives for the treatment of osteoporosis

Indole derivatives and their use for the treatment of osteoporosis amongst other applications

Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists

The present invention relates to a novel use, in particular a novel pharmaceutical use for a series of quinoline derivatives.

Quinoline derivatives as NK3 antagonists

Quinoline derivatives as NK-2 and NK-3 receptor ligands

Growing community of inventors

Milan, Italy

Carlo Farina